From Insights to Impact: How AI Is Transforming Pharmaceutical Competitive Intelligence
Mike Falvo
Executive Director, Management Advisor CI & AA
TGaS Advisors, a division of Trinity
Pharmaceutical competitive intelligence (CI) has quietly become one of pharma’s most strained functions. The TGaS Competitive Intelligence Landscape Survey (October 2025) shows competitive complexity accelerating at a pace that traditional CI models cannot absorb. The clinical-stage pipeline of new medicines more than doubled between 2019 and 2024 (Source: PMPRB, ISPOR 2025, using GlobalData data). Most pharma CI leaders expect flat or lower budgets and headcount over the next 12 months, even as a majority expect to track more competitors (Source: TGaS Advisors, Pharma CI Landscape Surveys, 2025–2026). Our field cannot keep taking on more with the same resources. Something has to give. Left unchanged, this model leads to missed signals, slower response times, and CI teams stretched past their limits.
To keep pace, CI must confront the limits of its current model, use AI to break the data bottleneck, and expand its mandate from informing strategy to shaping enterprise decisions.
The Limits of Traditional Pharma CI Operating Models
Pharma CI teams have traditionally spent much of their time collecting and monitoring public information. That collection-heavy model is breaking down because:
- Competitive data sources are increasingly fragmented.
- CI teams must track a growing number of competitors and brands.
- Many CI leaders now also own primary market research and other insight streams, leaving less time for core CI work.
Asking CI teams to hold this together with the same resources is not sustainable. This squeeze leaves little time for the work that creates value: interpreting signals and advising leadership. AI can take on more of the collection work, giving analysts more time to apply judgment.
How AI Is Reshaping Day-to-Day Pharma CI
AI-backed competitive intelligence changes how CI teams work. Nearly 8 in 10 biopharma leaders cite improved efficiency and productivity as AI’s primary near-term benefit (Source: TGaS Advisors AI in Biopharma Survey, Wave 7, April 2026). AI-powered monitoring, summarization, and alerting can now continuously process vast quantities of public information. Tasks that once took days or weeks can now take minutes. The immediate impact is clear: AI gives CI professionals time back.
In practical terms, AI can:
- Execute 24/7 competitor monitoring and real-time alerts: AI scans diverse sources 24/7 (websites, trial registries, news, social media, etc.) and sends immediate alerts for major competitor developments. This replaces manual periodic checks and ensures teams catch critical events as they happen.
- Automate signal filtering and early detection: AI filters out the flood of competitor updates, ranks signals by importance, and clusters related events to highlight weak signals early. This replaces time-consuming manual noise filtering and helps prevent missed or late insights.
- Rapidly synthesize and generate first-draft reporting: AI can auto-summarize competitor news and documents to create initial updates or slide drafts in minutes. This replaces hours of manual research and writing, giving CI professionals more time for deeper analysis.
- Auto-populate dynamic dashboards and forward-looking insights: AI auto-populates interactive CI dashboards with near real-time data and uses pattern detection to flag emerging trends or likely competitor moves. This provides actionable, forward-looking intelligence instead of static, retrospective reports.
But efficiency is only the entry point, not the end goal. The real opportunity is to redeploy this reclaimed time from collection to influence. CI can spend less time reporting what happened and more time explaining what it means and what to do next.
How CI Evolves from Brand Support to Enterprise Value Driver
As AI takes over routine data gathering, CI can shift from backward-looking reporting to forward-leaning, decision-shaping intelligence. This allows us to support functions far beyond our traditional brand and commercial teams. We can now contribute insights to R&D and clinical strategy, business development, corporate strategy, investor relations, and public affairs. In these areas, CI can shape high-impact business decisions and, ultimately, stock price.
In this evolved model, CI should be evaluated not on whether it informs strategy, but on whether it changes decisions. Success is measured by CI’s role in shaping strategic direction across R&D, Clinical, Commercial, BD, PR, and IR. That role should show up in earlier decisions, clearer strategic trade‑offs, more coordinated enterprise narratives, and measurable impact on company performance and stock price. The standard is measurable business impact, not just downstream adoption of CI inputs.
Future-state CI leaders must also develop new skills and mindsets that match this expanded role. That means spending less time producing decks and more time on interpretation, prediction, and influence. Success should be measured not by the volume of intelligence delivered, but by the quality of decisions informed.
What CI Leaders Should Do Next
Do not use AI just to do the same work faster; use it to intentionally redesign the CI role, expand its scope, and position CI as a source of measurable business impact. Over the next 12-24 months, CI leaders can:
- Redesign CI ownership, not just workflows: Explicitly assign CI accountability for shaping strategy across R&D, Clinical, BD, PR, and IR, not merely informing downstream teams.
- Reallocate CI time toward decision moments: Use AI to compress monitoring and synthesis so CI is consistently embedded before major decisions are made.
- Change success metrics from adoption to impact: Shift CI KPIs from usage and satisfaction to measurable influence on strategic direction, decision timing, and business outcomes.
- Build CI capability in narrative and influence: Invest in skills that help CI shape enterprise narratives for executives, investors, and external stakeholders, not just internal brand teams.
- Pilot enterprise-facing CI use cases: Start with one or two high-visibility decisions, such as pipeline prioritization, BD positioning, or investor messaging, where CI is expected to lead.
Within the TGaS CI network, leaders are already experimenting with these shifts. We invite you to share what’s working, and what isn’t, as CI leaders shape this AI era together.